Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001410578-25-000549
Filing Date
2025-03-31
Accepted
2025-03-31 08:18:31
Documents
89
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K mrkr-20241231x10k.htm   iXBRL 10-K 2058762
2 EX-19.1 mrkr-20241231xex19d1.htm EX-19.1 51225
3 EX-21.1 mrkr-20241231xex21d1.htm EX-21.1 1743
4 EX-23.1 mrkr-20241231xex23d1.htm EX-23.1 2172
5 EX-31.1 mrkr-20241231xex31d1.htm EX-31.1 12910
6 EX-31.2 mrkr-20241231xex31d2.htm EX-31.2 12434
7 EX-32.1 mrkr-20241231xex32d1.htm EX-32.1 5477
8 EX-32.2 mrkr-20241231xex32d2.htm EX-32.2 5481
9 GRAPHIC mrkr-20241231x10k001.jpg GRAPHIC 9553
10 GRAPHIC mrkr-20241231x10k002.jpg GRAPHIC 43432
11 GRAPHIC mrkr-20241231x10k003.jpg GRAPHIC 30594
12 GRAPHIC mrkr-20241231x10k004.jpg GRAPHIC 34725
13 GRAPHIC mrkr-20241231x10k005.jpg GRAPHIC 35691
14 GRAPHIC mrkr-20241231x10k006.jpg GRAPHIC 74641
15 GRAPHIC mrkr-20241231x10k007.jpg GRAPHIC 101759
16 GRAPHIC mrkr-20241231x10k008.jpg GRAPHIC 42366
17 GRAPHIC mrkr-20241231x10k009.jpg GRAPHIC 34727
  Complete submission text file 0001410578-25-000549.txt   8949836

Data Files

Seq Description Document Type Size
18 EX-101.SCH mrkr-20241231.xsd EX-101.SCH 56651
19 EX-101.CAL mrkr-20241231_cal.xml EX-101.CAL 41848
20 EX-101.DEF mrkr-20241231_def.xml EX-101.DEF 228773
21 EX-101.LAB mrkr-20241231_lab.xml EX-101.LAB 467932
22 EX-101.PRE mrkr-20241231_pre.xml EX-101.PRE 381999
92 EXTRACTED XBRL INSTANCE DOCUMENT mrkr-20241231x10k_htm.xml XML 1039254
Mailing Address 2450 HOLCOMBE BLVD SUITE BCM-A, MS: BCM251 HOUSTON TX 77021
Business Address 2450 HOLCOMBE BLVD SUITE BCM-A, MS: BCM251 HOUSTON TX 77021 (713) 400-6400
Marker Therapeutics, Inc. (Filer) CIK: 0001094038 (see all company filings)

EIN.: 880277072 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-37939 | Film No.: 25789030
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)